← All trials
NCT06131021
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2024
- Primary completion
- Jan 31, 2026
- Completion date
- May 26, 2026
- First posted
- Nov 14, 2023
- Last posted
- Nov 14, 2023
- Enrollment
- 544
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Rutgers UniversityLead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)Collaborator
- Rutgers UniversityReponsible party - principal investigator
- Rutgers UniversityOverall official - principal investigator
- Rutgers UniversityOfficial
- Rutgers UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.